Innovation in Ireland →
Managing director, the Foundry Group
Partner, Third Rock Ventures
Professor of Innovation at The University of Texas at Austin
CEO and Fund Manager, Renaissance Venture Capital Fund
VP of Research & Policy, Ewing Marion Kauffman Foundation
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
June 1, 2015 ·
June 17, 2015 ·
Acetylon is developing targeted HDAC inhibitor drugs.
Xconomy offers a number of ways to subscribe for free!
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin and beyond.
© 2007-2015, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Website development support from Andrew Koyfman with design support from Rob Hunter.